Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP9831 in non-alcoholic steatohepatitis
NCT00668070Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 2008
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of asp9831 in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Astellas Pharma. Primary endpoint: Alanine Aminotransferase at 12 weeks. Started Apr 2008; status: completed.
02
Drugs
asp9831
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT00668070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00668070.